Natural history of stage IV epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 767-775

  Bonnefoi, H ^a   A'Hern, R P ^a   Fisher, C ^a   MacFarlane, V ^a   Barton, D ^a   Blake, P ^a   Shepherd, J H ^a   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032977940     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.767     Document Type: Article

References (39)

1. OPCS Mortality Statistics DH2: Cause, England and Wales, 1986. London, United Kingdom, Her Majesty's Stationary Office, 1993
2. Beral V: The epidemiology of ovarian cancer, in Sharp F, Soutter WP (eds): Ovarian Cancer: the Way Ahead. London, England, Royal College of Obstetrics and Gynecology, 1987, pp 21-32
3. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995 [published correction appears in CA Cancer J Clin 45:127-128, 1995]. CA Cancer J Clin 45:8-30, 1995
4. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995 [published correction appears in CA Cancer J Clin 45:127-128, 1995]. CA Cancer J Clin 45:8-30, 1995
5. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995 [published correction appears in CA Cancer J Clin 45:127-128, 1995]. CA Cancer J Clin 45:8-30, 1995
6. Pettersson F: Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 22:83-102, 1994 (suppl)
7. Ahmed FY, Wiltshaw E, A'Hern RP, et al: Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 14:2968-2975, 1996
8. Pettersson F: Annual report of the results of treatment of gynaecological cancer. International Federation of Gynaecology and Obstetrics (FIGO), Stockholm, Sweden, 1988
9. International Federation of Gynecology and Obstetrics: Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156:263-264, 1987
10. Barker GH, Wiltshaw E: Randomised trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil, and doxorubicin in advanced ovarian carcinoma. Lancet 1:747-750, 1981
11. Wiltshaw E, Evans B, Rustin G, et al: A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 4:722-729, 1986
12. Taylor AE, Wiltshaw E, Gore ME, et al: Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial cancer. J Clin Oncol 12:2066-2070, 1994
13. Perren TJ, Gore ME, Fryat I, et al: High dose carboplatin for stage IV ovarian carcinoma: A preliminary analysis of response, toxicity and survival. Proc Am Soc Clin Oncol 7:147, 1988 (abstr 568)
14. Hardy JR, Wiltshaw E, Blake PR, et al: Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Ann Oncol 2:131-136, 1991
15. Gore ME, Rustin G, Slevin M, et al: Single agent paclitaxel in previously untreated patients with stage IV epithelial ovarian cancer. Br J Cancer 75:710-714, 1997
16. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO publication no. 48. Geneva, Switzerland, World Health Organization, 1979
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
18. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
19. Cox DR: Regression models and life tables (with discussion) J R Stat Soc 30:248-275, 1972
20. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Randomised trial comparing two combination chemotherapy regimens (HEXA-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 2:594-600, 1984
21. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol 5:1157-1168, 1987
22. Grouppo Interegionale Cooperativo Oncologico Ginecologia: Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 2:353-359, 1987
23. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stage III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992
24. Swenerton K, Jeffrey J, Stuart G, et al: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718-726, 1992
25. Kaye SB, Paul J, Cassidy J, et al: Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14:2113-2119, 1996
26. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
27. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus cisplatin plus intravenous cyclophosphamide for stage Ill ovarian cancer. N Engl J Med 335:1950-1955, 1997
28. Alberts DS, Dahlberg S, Green SJ, et al: Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. Cancer 71:618-627, 1993
29. Thigpen T, Brady MF, Omura G, et al: Age as a prognostic factor in ovarian carcinoma: The Gynecologic Oncology Group Experience. Cancer 71:606-614, 1993
30. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Long-term survival in ovarian cancer. Eur J Cancer 11:1367-1372, 1991
31. Berek JS: Interval debulking of ovarian cancer: An interim measure. N Engl J Med 332:675-677, 1995 (editorial)
32. Goodman HM, Harlow BL, Sheets E, et al: The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 46:367-371, 1992
33. Curtin JP, Malik R, Venkatraman ES, et al: Stage IV ovarian cancer: Impact of surgical debulking. Gynecol Oncol 64:9-12, 1997
34. Liu PC, Benjamin I, Morgan M, et al: Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 64:4-8, 1997
35. Munkarah A, Hallum AV, Morris M, et al: Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 64:13-17, 1997
36. Wils G, Blijham G, Naus A, et al: Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 4:1068-1073, 1986
37. Jacob JH, Gershenson DM, Morris M, et al: Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 42:146-150, 1991
38. Potter ME, Partridge EE, Hatch KD, et al: Primary surgical therapy of ovarian cancer: How much and when. Gynecol Oncol 40:195-200, 1991
39. Van der Burg MEL, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332:629-634, 1995